

The background of the poster features a dark purple and blue color scheme with large, overlapping circular shapes. On the right side, there is a circular inset image showing a city skyline at dusk, with buildings illuminated and their lights reflecting on the water. The text is primarily in white and purple, with a mix of bold and regular fonts.

ASH 2024

66th ASH Annual Meeting and Exposition

December 7–10, 2024
San Diego, US

 **MultipleMyelomaHub**

TOP ABSTRACTS

To help navigate the exciting content being presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7–10, 2024, San Diego, US, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

ASH 2024: Top abstracts in MM

December 7–10, 2024

Newly diagnosed multiple myeloma			
Abstract	Title	Speaker	Date and time (PT)
257 View	Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)	Smith Giri	Saturday, December 7, 2024, 15:00
362 View	Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial	Sonja Zweegman	Saturday, December 7, 2024, 16:15
363 View	Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation	Luciano J. Costa	Saturday, December 7, 2024, 16:30
489 View	Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis	Noemi Puig	Sunday, December 8, 2024, 10:00
493 View	Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial	Marc S. Raab	Sunday, December 8, 2024, 09:30
494 View	Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestic-4/EMN30 Trial	Elena Zamagni	Sunday, December 8, 2024, 09:45
497 View	Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis	Saad Z. Usmani	Sunday, December 8, 2024, 10:30
675 View	Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups	Laahn Foster	Sunday, December 8, 2024, 17:00
678 View	GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation	Maria-Victoria Mateos	Sunday, December 8, 2024, 17:45

Abstract	Title	Speaker	Date and time (PT)
769 View	Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)	Hartmut Goldschmidt	Monday, December 9, 2024, 10:30
774 View	The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma	Salomon Manier	Monday, December 9, 2024, 11:45

Relapsed/ refractory multiple myeloma

Abstract	Title	Speaker	Date and time (PT)
79 View	Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma	Joshua Gustine	Saturday, December 7, 2024, 09:30
81 View	24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702	Rahul Banerjee	Saturday, December 7, 2024, 10:00
83 View	Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma	Jean-Sébastien Claveau	Saturday, December 7, 2024, 10:30
256 View	Effects of Intravenous Immunoglobulin Supplementation (IVIg) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study	Heloise Cheruvalath	Saturday, December 7, 2024, 14:45
366 View	Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma	Daisuke Ikeda	Saturday, December 7, 2024, 17:15
495 View	Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestic-2 Cohort a and Trimm-2 Studies	Anita D'Souza	Sunday, December 8, 2024, 10:00
677 View	Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial	Luciano J. Costa	Sunday, December 8, 2024, 17:30
772 View	Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial	Vania Hungria	Monday, December 9, 2024, 11:15

Abstract	Title	Speaker	Date and time (PT)
895 View	Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma	Kai Rejeski	Monday, December 9, 2024, 14:45
896 View	Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma	Doris K. Hansen	Monday, December 9, 2024, 15:00
897 View	Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium	Danai Dima	Monday, December 9, 2024, 15:15
900 View	Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients	Bruno Paiva	Monday, December 9, 2024, 16:00
922 View	Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)	Susan Bal	Monday, December 9, 2024, 15:30
931 View	Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)	Binod Dhakal	Monday, December 9, 2024, 14:45
932 View	Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab	Andrew Kowalski	Monday, December 9, 2024, 15:00
1023 View	Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma	Emma Searle	Monday, December 9, 2024, 17:00
1025 View	Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial	Irwindeep Sandhu	Monday, December 9, 2024, 17:30
1026 View	First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	Hang Quach	Monday, December 9, 2024, 17:45
1030 View	Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma	Eyal Lebel	Monday, December 9, 2024, 17:15

Abstract	Title	Speaker	Date and time (PT)
1031 View	Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial	Ciara Louise Freeman	Monday, December 9, 2024, 17:30
1032 View	Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial	Rakesh Popat	Monday, December 9, 2024, 17:45
4695 View	Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma	Nadine Abdallah	Monday, December 9, 2024, 18:00

Other plasma cell dyscrasias

Abstract	Title	Speaker	Date and time (PT)
488 View	Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma	Nayda Bidikian	Sunday, December 8, 2024, 09:45
773 View	Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study	Meletios-Athanasios Dimopoulos	Monday, December 9, 2024, 11:30
891 View	Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study	Efstathios Kastritis	Monday, December 9, 2024, 15:15
893 View	Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study	Kaini Shen	Monday, December 9, 2024, 15:45
1027 View	Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma	Omar Nadeem	Monday, December 9, 2024, 16:30



#ASH24

Follow us on X to keep up to date
with the latest from the congress

@MM_Hub

 **MultipleMyelomaHub**

Brought to you by

